Novartis Typhoid Vaccine Deal With India’s BioE Shows New Licensing Model
This article was originally published in The Pink Sheet Daily
Executive Summary
Biological E Limited will develop Novartis’ Vi-CRM197 beyond Phase II; the firm will gain rights to a second vaccine against typhoid and paratyphoid upon completion of proof of concept studies.